Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY-NC-ND 4.0Scientific Reports

Linking surfactant proteins and genetic variants to COVID-19 severity

4 affiliations
  1. 1Department of Pediatrics, The Pennsylvania State College of Medicine, Room. C7744, H085, 500 University Drive, P.O. Box 850, Hershey, PA 17033-0850 USA
  2. 2Department of Public Health Science, The Pennsylvania State College of Medicine, Hershey, PA USA
  3. 3Present Address: Department of Pediatrics, Brown University, Providence, RI USA
  4. 4Present Address: Department of Obstetrics and Gynecology, UPMC Harrisburg, Harrisburg, PA USA

Abstract

COVID-19 presents with variable clinical severity. Surfactant proteins (SPs) are critical to lung function and host defense, but their role as biomarkers for COVID-19 severity, and the impact of SP genetic variants, remains unclear. Therefore, we asked whether plasma SP levels and SP genetic variants are associated with COVID-19 severity in adults. We conducted a cohort study of 261 adults with PCR-confirmed COVID-19, classified as non-severe (n = 117) or severe (n = 144) based on WHO severity criteria. Plasma SP-A, SP-B, and SP-D levels were measured. Genetic variants in SFTPA1, SFTPA2, SFTPB, SFTPC, and SFTPD were analyzed. Quantile regression, receiver operating curve analysis, and logistic regression were used to assess associations. To compare model performance, the corrected Akaike Information Criterion (AICC) was used. Mediation analysis evaluated interactions among SP-A levels, genetic variant and disease severity. Severe COVID-19 was associated with higher plasma SP-A (9.8 vs. 8.4 ng/mL, p = 0.04) and SP-B (4119.2 vs. 3137.2 ng/mL, p = 0.01) levels, but not SP-D. SP-A and SP-B showed moderate predictive value for severity (AUC = 0.71). Inclusion of plasma SP-A (AICC = 219.7) or SP-B (AICC = 221.0) levels along with demographics improved performance over the demographics-only model (AICC = 300.2). Although significance was lost after Bonferroni correction, rs10351 in SFTPA1 was associated with lower risk of severe disease (OR = 0.40, p = 0.03); and lower SP-A level. Mediation analysis suggested the association was driven by disease severity. No associations were found for other SP gene variants. Elevated SP-A and SP-B levels are associated with severe COVID-19 and may serve as biomarkers. Predictive models combining either SP-A or SP-B levels with clinical information offer strong potential for risk stratification. The SFTPA1 variant rs10351 may confer protection through reduced alveolar injury, though further validation is warranted.

Clinical trial registration: ClinicalTrials.gov. Study ID# NCT04650191, 30th November, 2020.

Related

  1. Association of EGLN1 and EGLN3 genetic variants with COVID-19 severity in a Mexican population
    Laura E. Martínez-Gómez, Eliurde Valle-Rivera, Carlos Martinez-Armenta +20
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textInfectious diseaseCrossref
  2. Natural genetic diversity modulates structural stability changes caused by pathogenic variants in small proteins
    T. Niemeijer, M. A. Swertz, K. J. van der Velde
    medRxivPreprintCC BYFull textHuman geneticsmedRxiv
  3. Genetic and transcriptomic evidence linking IFNG +874T/A and IFN-γ signaling to COVID-19 severity
    Mohammad Samet, Faezeh Niknam, Masoud Tajamolian +5
    Scientific ReportsPeer-reviewedCC BYFull textInfectious diseaseDOAJ
  4. Beyond illness severity: transdiagnostic cognitive vulnerabilities as independent predictors of psychological distress in parents of children with rare genetic disorders
    Goran Cuturilo, Tatjana Vukosavljevic Gvozden, Matija Gvozden +2
    Frontiers in psychiatryPeer-reviewedCC BYFull textPsychiatry & mental healthEurope PMC
  5. Gene-environment interaction between VDR variants and vitamin D deficiency identifies a high-risk inflammatory phenotype associated with COVID-19 severity
    HariOm Singh, Aishwarya Nair, Meenakshi Bhattacharya +2
    Scientific ReportsPeer-reviewedCC BYFull textEndocrinology & metabolismDOAJ
BibTeX
@article{aldrich2026linking,
  title = {{Linking surfactant proteins and genetic variants to COVID-19 severity}},
  author = {Brycen Aldrich and Natalie Sicher and Shaoyi Zhang and Lauren Mazur and Catherine M. Roberts and Erik Lehman and Dajiang Liu and Chintan K. Gandhi},
  journal = {Scientific Reports},
  year = {2026},
  month = aug,
  doi = {10.1038/s41598-026-66542-w},
  url = {https://doi.org/10.1038/s41598-026-66542-w},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Linking surfactant proteins and genetic variants to COVID-19 severity
AU  - Brycen Aldrich
AU  - Natalie Sicher
AU  - Shaoyi Zhang
AU  - Lauren Mazur
AU  - Catherine M. Roberts
AU  - Erik Lehman
AU  - Dajiang Liu
AU  - Chintan K. Gandhi
PY  - 2026
DA  - 2026/08/14
JO  - Scientific Reports
DO  - 10.1038/s41598-026-66542-w
UR  - https://doi.org/10.1038/s41598-026-66542-w
AB  - COVID-19 presents with variable clinical severity. Surfactant proteins (SPs) are critical to lung function and host defense, but their role as biomarkers for COVID-19 severity, and the impact of SP genetic variants, remains unclear. Therefore, we asked whether plasma SP levels and SP genetic variants are associated with COVID-19 severity in adults. We conducted a cohort study of 261 adults with PCR-confirmed COVID-19, classified as non-severe (n = 117) or severe (n = 144) based on WHO severity criteria. Plasma SP-A, SP-B, and SP-D levels were measured. Genetic variants in SFTPA1, SFTPA2, SFTPB, SFTPC, and SFTPD were analyzed. Quantile regression, receiver operating curve analysis, and logistic regression were used to assess associations. To compare model performance, the corrected Akaike Information Criterion (AICC) was used. Mediation analysis evaluated interactions among SP-A levels, genetic variant and disease severity. Severe COVID-19 was associated with higher plasma SP-A (9.8 vs. 8.4 ng/mL, p = 0.04) and SP-B (4119.2 vs. 3137.2 ng/mL, p = 0.01) levels, but not SP-D. SP-A and SP-B showed moderate predictive value for severity (AUC = 0.71). Inclusion of plasma SP-A (AICC = 219.7) or SP-B (AICC = 221.0) levels along with demographics improved performance over the demographics-only model (AICC = 300.2). Although significance was lost after Bonferroni correction, rs10351 in SFTPA1 was associated with lower risk of severe disease (OR = 0.40, p = 0.03); and lower SP-A level. Mediation analysis suggested the association was driven by disease severity. No associations were found for other SP gene variants. Elevated SP-A and SP-B levels are associated with severe COVID-19 and may serve as biomarkers. Predictive models combining either SP-A or SP-B levels with clinical information offer strong potential for risk stratification. The SFTPA1 variant rs10351 may confer protection through reduced alveolar injury, though further validation is warranted.  Clinical trial registration: ClinicalTrials.gov. Study ID# NCT04650191, 30th November, 2020.
SN  - 2045-2322
ER  -